Cargando…

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies

BACKGROUND: SARS-CoV-2 vaccines currently authorized for emergency use have been highly successful in preventing infection and lessening disease severity. The vaccines maintain effectiveness against earlier SARS-CoV-2 Variants of Concern but the heavily mutated, highly transmissible Omicron variant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Takuya, Zhou, Hao, Dcosta, Belinda M., Samanovic, Marie I., Chivukula, Vidya, Herati, Ramin S., Hubbard, Stevan R., Mulligan, Mark J., Landau, Nathaniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021600/ https://www.ncbi.nlm.nih.gov/pubmed/35465948 http://dx.doi.org/10.1016/j.ebiom.2022.103944

Ejemplares similares

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
por: Tada, Takuya, et al.
Publicado: (2022)

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2021)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Tada, Takuya, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
por: Noval, Maria G., et al.
Publicado: (2021)

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
por: Benotmane, Ilies, et al.
Publicado: (2022)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron
por: Laurie, Matthew T, et al.
Publicado: (2022)

SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron
por: Laurie, Matthew T, et al.
Publicado: (2021)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
por: Ju, Bin, et al.
Publicado: (2023)

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
por: Lyke, Kirsten E., et al.
Publicado: (2022)

Multimodal characterization of antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
por: Ju, Bin, et al.
Publicado: (2023)

Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
por: Schulz, Sebastian R., et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

Multimodal single-cell datasets characterize antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
por: Tada, Takuya, et al.
Publicado: (2020)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
por: Peng, Pai, et al.
Publicado: (2022)

Omicron infection elicits a broad neutralizing response in hospitalized patients with COVID-19
por: McNally, Elizabeth M.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
por: Jacobsen, Henning, et al.
Publicado: (2022)

Neutralization, effector function and immune imprinting of Omicron variants
por: Addetia, Amin, et al.
Publicado: (2023)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022)

Designer antigens for elicitation of broadly neutralizing antibodies against HIV
por: Kok, Tuckweng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kkmukgtg7fjonjoh79me6li3gf